The Partners

The Partners

TOVA Initiative represents a collaborative effort between a team of experienced investigators who have been working together on river blindness for 30 years. These investigators are supported by young scientists with expertise ranging from mathematical modelling, through immunology, proteomics and genomics, vaccinology and product development to clinical practice. TOVA Initiative will adopt the Product Development Partnership (PDP) approach used by the Sabin PDP for accelerating the development of new vaccines for global health.

Name Participant’s organization, country Role in the Partnership
The partners from Africa
Prof Samuel Wanji University of Buea, Cameroon Research Foundation in Tropical Disease and Environment Human studies in Cameroon
Dr Vincent Tanya Cameroon Academy of Sciences Screening vaccine candidates in the O ochengi cow model
Dr Alex Debrah Kwame Nkrumah University, Ghana Human studies in Ghana
The partners from Europe
Prof David W Taylor University of Edinburgh, UK Co-ordinator of the EU consortium. Vaccine development and human studies in Cameroon
Dr Ben Makepeace
 
University of Liverpool, UK Proteomic and genomic analyses and vaccine development. Screening vaccine candidates in the O ochengi cattle model. Host gene expression profile analysis
Dr Simon Babayan University of Glasgow, UK Filarial immunology, vaccine development and screening vaccine candidates in the L sigmodontis mouse model
Dr Coralie Martin Muséum National d’Histoire Naturelle, Paris, France Screening vaccine candidates in the L sigmodontis mouse model. Host gene expression profile analysis
Prof Achim Hoerauf University Hospital of Bonn, Germany Immunology of filarial infections and human studies in Ghana. Host gene expression profile analysis
Prof María Gloria Basáñez Imperial College London, UK Mathematical modelling and cost-effectiveness
The partners from USA
Dr Sara Lustigman New York Blood Center, NYC, USA Program Director of the NIH funded consortium. Human studies in Cameroon, characterization of vaccine candidates
Prof David Abraham Thomas Jefferson University, Philadelphia, PA, USA Screening vaccine candidates in the PA, USA O volvulus mouse model
Prof Thomas Klei Louisiana State University, Baton Rouge, LA, USA Screening vaccine candidates in the Brugia malayi-jird model
Prof Maria Elena Bottazi
Prof Peter Hotez
National School of Tropical Medicine, Baylor College of Medicine, and Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA Product development, technology transfer for cGMP manufacture and GLP toxicology testing, regulatory filing, early stage clinical testing
Dr Darrick Carter PAI Life Sciences Seattle, WA Product development, cGMP manufacture